A Pilot Trial of Cytosine Deaninase-Expressing Mesenchymal Stromal Cells in Glioblastoma Therapy
 |
Peter Black, MD, PhD
Boston Children's
Hospital, Brigham
and Women'sHospital,
Harvard Medical School,
Dana-Farber Institute |
Glioblastoma (GBM) is among the most aggressive and treatment-resistant of all human cancers, with a typical life expectancy of 9–15 months after diagnosis. A new therapeutic strategy, developed by Dr. Peter Black and his multidisciplinary team at BWH, aims to provide new hope to patients diagnosed with this primary brain tumor.
Dr. Black’s groundbreaking clinical trial uses a specific type of the body’s own bone marrow cells, genetically modified, to directly target and destroy the tumor cells and significantly reduce their growth. This clinical trial will soon accept adult patients and holds great promise for expanding the use of gene therapy in brain cancer treatment.